Literature DB >> 2023754

Corticosteroids in corneal graft rejection. Oral versus single pulse therapy.

J C Hill1, R Maske, P Watson.   

Abstract

Forty-eight patients with corneal grafts with severe endothelial rejection were randomly assigned to two treatment groups. One group of 24 patients received prednisolone acetate 1% drops hourly and a single intravenous pulse of 500 mg methylprednisolone. The other group of 24 patients received the same topical therapy plus oral prednisone 60 to 80 mg daily. Nineteen (79.2%) grafts survived in the group that received pulse therapy compared with 15 (62.5%) grafts in the oral group; the difference was not significant (P = 0.17). However, in patients who sought treatment early (less than or equal to 8 days) survival rates were 92.3% and 54.5%, respectively, which indicated a significant advantage for pulse therapy (P less than 0.05). Pulse therapy also appeared beneficial in preventing subsequent rejection episodes. Five (26.3%) of the 19 surviving grafts in the group that received pulse therapy had a further rejection episode compared with 10 (66.7%) of the surviving 15 grafts in the oral group; the difference is significant (P less than 0.025).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2023754     DOI: 10.1016/s0161-6420(91)32291-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

Review 1.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Immunology of corneal transplantation.

Authors:  W H Constad; K Taraschanskiy
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

Review 4.  [Immunomodulation in penetrating keratoplasty. Current status and perspectives].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

5.  [Current practice of immune prophylaxis and therapy in perforating keratoplasty. A survey of members of the Cornea Section of the German Ophthalmological Society].

Authors:  E Bertelmann; T Reinhard; U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

Review 6.  Pharmacokinetics of ophthalmic corticosteroids.

Authors:  C N McGhee
Journal:  Br J Ophthalmol       Date:  1992-11       Impact factor: 4.638

7.  Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection.

Authors:  T Hudde; D C Minassian; D F Larkin
Journal:  Br J Ophthalmol       Date:  1999-12       Impact factor: 4.638

Review 8.  Corneal allograft rejection.

Authors:  D F Larkin
Journal:  Br J Ophthalmol       Date:  1994-08       Impact factor: 4.638

9.  Effects of immunosuppressants after penetrating keratoplasty: meta-analysis of randomized controlled trials.

Authors:  Xin Wei; Xiao-Ming Chen; Lin Wang; Jin-Ping Song; Yin-Ping Deng
Journal:  Int J Ophthalmol       Date:  2011-10-18       Impact factor: 1.779

10.  In Vivo Characteristics of Corneal Endothelium/Descemet Membrane Complex for the Diagnosis of Corneal Graft Rejection.

Authors:  Mohamed Abou Shousha; Sonia H Yoo; Mohamed S Sayed; Sean Edelstein; Matthew Council; Ravi S Shah; Joshua Abernathy; Zachary Schmitz; Patrick Stuart; Rocio Bentivegna; Maria P Fernandez; Christopher Smith; Xiaotang Yin; George J Harocopos; Sander R Dubovy; William J Feuer; Jianhua Wang; Victor L Perez
Journal:  Am J Ophthalmol       Date:  2017-03-02       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.